Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

ASCO 2025: Latest updates in mRCC

Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier...

ASCO 2025: Latest updates in mRCC ( Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier Puente )

Prophylactic tocilizumab prior to infusion of anti-CD19 CAR-T ce may reduce...

Dr Wiebke Rösler - University Hospital Zurich, Zurich, Switzerland

Prophylactic tocilizumab prior to infusion of anti-CD19 CAR-T ce may reduce toxicity in older lymphoma patients ( Dr Wiebke Rösler - University Hospital Zurich, Zurich, Switzerland )

Optimising immunoglobulin dosing can enhance patient outcomes in multiple...

Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA

Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma ( Dr Elizabeth O'Donnell - Dana-Farber Cancer Institute, Boston, USA )

High-fibre dietary intervention in precursor plasma cell disorders improves...

Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA

High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma ( Dr Urvi Shah - Memorial Sloan Kettering Cancer Center, New York, USA )

Lack of benefit of auto-HCT in MCL patients in first complete remission with...

Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA

Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD ( Dr Robert Dean - Cleveland Clinic Taussig Cancer Center, Cleveland, USA )

KRdc as induction therapy shows improved OS for NDMM patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

KRdc as induction therapy shows improved OS for NDMM patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk...

Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer ( Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA )

Teclistamab-lenalidomide and teclistamab alone can be safely administered as...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus...

Dr Adam Olszewski - Brown University, Providence, USA

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL ( Dr Adam Olszewski - Brown University, Providence, USA )

Acalabrutinib plus venetoclax with or without obinutuzumab versus...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Primary IVIG supplementation reduces the risk of high-grade infections in...

Dr Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA

Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM ( Dr Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA )

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows...

Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma ( Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA )

More from ecancer